Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896–903
Carmichael J, Popiela T, Radstone D, Falk S, Fey M, Oza A, Skovsgaard T and Martin C (1999) Randomized comparative study of ORZEL (oral uracil/tegafur (UFT) plus leucovorin) versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 264a
Cox JV, Pazdur R, Thibault A, Maroun J, Weaver C, Jahn MW, Harrison E and Griffin T (1999) A phase III trial (SO 14695) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 265a
Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D and Perez Manga G (1996) Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. ‘Tomudex’ Colorectal Cancer Study Group. Ann Oncol 7: 961–965
Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen T, Starkhammar H, Topham CA, Awad L, Jacques C and Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413–1418
de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214–219
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041–1047
Farrugia DC, Norman AR and Cunningham D (1998) Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer. Eur J Cancer 34: 987–991
Ford HER, Farrugia DC, Cunningham D, Aherne GW, Hardcastle A, Mitchell F, Hill ME, McCarthy K, McVicar D, Danenberg PV, Danenberg K and Jackman AL (2000) High thymidylate synthase mRNA expression may predict non-response in tumor and increased risk of toxicity in normal gastrointestinal mucosa following treatment with raltitrexed (‘Tomudex’) (abstract). Proc Am Soc Clin Oncol 19: 243a
Giacchetti S, Zidani R and Perpoint B (1997) Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 16: 229a
Giacchetti S, Brienza S, Focan C, Metouri A, Perpoint B, Faggiuolo R, Llory JF, Le Rol A, Larregain-Fournier D, Tigaud JM, Debotte G, Itzhaki M, Misset JL and Levi F (1998) Contribution of second line oxaliplatin-chronomodulated 5-fluorouracil-folinic acid and surgery to survival in metastatic colorectal cancer patients (abstract). Proc Am Soc Clin Oncol 17: 273a
Goldwasser F, Gross M, Tigaud JM, Jasmin C, Marceau-Suissa J, Misset JL and Cvitkovic E (1999) CPT-11/Oxaliplatin combination every two weeks: Final results of a phase I study in advanced digestive malignancies (abstract). Proc Am Soc Clin Oncol 18: 176a
Harper P (1997) Advanced colorectal cancer: results from the last (raltitrexed) Tomudex comparative study (abstract). Proc Am Soc Clin Oncol 16: 228a
Hughes AN, Rafi I, Griffin MJ, Calvert AH, Newell DR, Calvete JA, Johnston A, Clendeninn N and Boddy AV (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clin Cancer Res 5: 111–118
Janinis J, Fountzilas G, Skarlos DV, Efstathiou E, Aravantinos G and Papakostas P (1999) Second-line combination chemotherapy with weekly oxaliplatin and high dose 5-fluorouracil with leucovorin in metastatic colorectal cancer. A Hellenic Cooperative Oncology Group study (abstract). Proc Am Soc Clin Oncol 18: 255a
Jodrell DI, Bowman A, Rye R, Byrne B, Boddy A, Rafi I, Taylor GA, Johnston A and Clendeninn NJ (1999) A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer 79: 915–920
Kemeny N, Tong W, Stockman J, Blanchette J and Saltz L (2000) Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 19: 245a
Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223–3229
Maindrault-Goebel F, De Gramont A, Louvet C, Andre T, Carola E, Gilles-Amar V, Izrael V, Molitor JL and Krulik M (1998) Bi-monthly oxaliplatin with leucovorin and 5-fluorouracil in pretreated metastatic colorectal cancer (FOLFOX 6) (abstract). Proc Am Soc Clin Oncol 17: 273a
Maindrault-Goebel F, De Gramont A, Louvet C, Andre T, Carola E, Gilles-Amar V, Lotz JP, Izrael V and Krulik M (1999) High-dose oxaliplatin with the simplified 48 h bimonthly leucovorin and 5-fluorouracil regimen in pretreated metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 265a
Maughan TS, James RD, Kerr D, McArdle C, Ledermann JA, Seymour M, Johnston C and Stephens RJ (1999) Preliminary results of a multicentre randomised trial comparing three chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 262a
Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308
Pazdur R and Vincent M (1997) Raltitrexed (Tomudex) vs 5-fluorouracil + leucovorin in patients with advanced colorectal cancer: results of a randomised multicentre North American trial (abstract). Proc Am Soc Clin Oncol 16: 228a
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ Jones DV, Jr, Markowitz AB, Abbruzzese JL, Bready B and Levin B (1994) Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296–2300
Pazdur R, Douillard J-Y, Skillings JR, Eisenberg PD, Davidson N, Harper P, Vincent MD, Lembersky BC and Benner SE (1999) Multicentre phase III study of UFT in conbination with leucovorin in patients with metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 263a
Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R and Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995–1001
Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P and Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407–1412
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322–1327
Saltz LB, Locker PK, Pirotta N, Elfring GL and Miller LL (1999) Weekly irinotecan, leucovorin, and fluorouracil is superior to daily × 5 LV/FU in patients with previously untreated metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 233a
Saltz LB, Douillard J, Pirotta N, Awad L, Elfring GL, Gruia G, Locker PK, Alakl M, Knight RD and Miller LL (2000) Combined analysis of two phase III randomised trials comparing irinotecan, fluorouracil, leucovorin versus fluorouracil alone as first-line therapy of previously untreated metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 19: 242a
Tournigand C, Louvet C, André T, Achille E, Lledo G, Flesch M, Ganem G, Landi B, Risse M-L, Lotz V, Colin P and de Gramont A (2000) FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer: Which is the best sequence? Safety and preliminary efficacy results of a randomized phase III study (abstract). Proc Am Soc Clin Oncol 19: 245a
Twelves C, Harper P, Van Cutsem E, Thibault A, Shelygin YA, Burger HU, Allman D and Osterwalder B (1999) A phase III trial (SO 14796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 263a
Van Cutsem E, Szanto J, Roth A, Humblet Y, Köhne CH, Wils J, Lorenz M, Borner M, Schöffski P and Tabah-Fisch I (1999) Evaluation of the addition of oxaliplatin to the same Mayo or German 5FU regimen in advanced refractory colorectal cancer (abstract). Proc Am Soc Clin Oncol 18: 234a
Wasserman E, Kalla S, Misset JL, Goldwasser F, Bedairia N, Bensamine MA, Marty M and Cvitkovic E (1999) Oxaliplatin and irinotecan phase I/II studies: Results in 5-FU refractory colorectal cancer patients (abstract). Proc Am Soc Clin Oncol 18: 238a
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Waters, J., Cunningham, D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 84, 1–7 (2001). https://doi.org/10.1054/bjoc.2000.1552
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1552
This article is cited by
-
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer
Investigational New Drugs (2011)
-
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy
Journal of Cancer Research and Clinical Oncology (2007)
-
Pioglitazone, a synthetic ligand for PPARγ, induces apoptosis in RB-deficient human colorectal cancer cells
Apoptosis (2006)
